Construction of Gynecological Tumor Organoids

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06155370
Collaborator
(none)
200
12

Study Details

Study Description

Brief Summary

This study focuses on the construction of a biological sample library for organoids and tumor tissues in gynecological tumors.

Condition or Disease Intervention/Treatment Phase
  • Other: construction of organoids from gynecological tumor

Detailed Description

Explore the construction and maintenance of a large-scale queue of gynecological tumor organoids. Beijing Daxiang Technology Co., Ltd. provides corresponding technical support and chip design. Gynecological oncology center provides tumor samples, clinical information, and pathological support, and biological sample library provides technical support, storage space, and quality management.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Construction of Gynecological Tumor Organoids
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
cohort of cervical cancer organoids

organoids derived from cervical cancer

Other: construction of organoids from gynecological tumor
organoids construction

cohort of endometrial cancer organoids

organoids derived from endometrial cancer

Other: construction of organoids from gynecological tumor
organoids construction

cohort of ovarian cancer organoids

organoids derived from ovarian cancer

Other: construction of organoids from gynecological tumor
organoids construction

cohort of vulva cancer organoids

organoids derived from vulva cancer

Other: construction of organoids from gynecological tumor
organoids construction

cohort of vaginal cancer organoids

organoids derived from vaginal cancer

Other: construction of organoids from gynecological tumor
organoids construction

cohort of gestational trophoblastic tumor organoids

organoids derived from gestational trophoblastic tumor

Other: construction of organoids from gynecological tumor
organoids construction

Outcome Measures

Primary Outcome Measures

  1. Construction of BioBank [one year]

    BioBank including organoids banks, tissue banks, PDX banks, immune cell banks, and primary banks from other tissue sources

Secondary Outcome Measures

  1. Drug sensitivity detection based on organoids banks [one year]

    Exploring drug sensitivity detection in gynecological tumors based on organoid libraries

  2. Exploring the molecular mechanism based on organoids banks [one year]

    Exploring the molecular mechanism of gynecological tumor pathogenesis based on organoid banks

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
Female
Inclusion Criteria:
  1. Age of 18 or older, an informed consent form is provided;

  2. The preoperative tumor burden assessment and intraoperative researcher team believe that sampling is feasible;

  3. Having relevant requirements for sample library storage;

  4. Surgical treatment at Peking Union Medical College Hospital.

Exclusion Criteria:
  1. Unable to meet all inclusion criteria;

  2. The research team considers any situations or considerations that may hinder normal pathological assessment.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lei Li, professor, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT06155370
Other Study ID Numbers:
  • K4903 G&O organoids
First Posted:
Dec 4, 2023
Last Update Posted:
Dec 4, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Dec 4, 2023